RxDoctor Payments Data

Thomas Wagner, MD

Family Medicine · College Station, TXNPI 1639131659

Payments from drug & device makers

$855in general payments, 2019–2025

Across 11 payments — averaging $77.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$237
  • Novo Nordisk$206
  • Pfizer$135
  • Bayer$123
  • Amgen$95
  • AbbVie$21
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$237
Novo Nordisk2$206
Pfizer2$135
Bayer1$123
Amgen1$95
AbbVie1$21
Dexcom, Inc.1$20
GSK1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$73,268
Medicare patients
236
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$132,932
OzempicSemaglutide100$126,037
EliquisApixaban65$77,903
RybelsusSemaglutide38$67,964
JanuviaSitagliptin Phosphate29$30,180
XareltoRivaroxaban17$22,864
FarxigaDapagliflozin Propanediol17$17,508
Rosuvastatin Calcium416$8,825
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$8,561
JanumetSitagliptin Phos/Metformin Hcl13$8,559
EntrestoSacubitril/Valsartan12$7,598
Losartan Potassium443$7,562
Gabapentin286$7,426
Ezetimibe-SimvastatinEzetimibe/Simvastatin39$6,246
Metoprolol Succinate252$6,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$206$194,001138 claims
PfizerEliquis$135$77,90365 claims
AstraZenecaFarxiga$237$17,50817 claims
AbbVieSynthroid$21$1,53941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in College Station

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →